Document Detail

Topical cyclosporine a in the treatment of superior limbic keratoconjunctivitis: a long-term follow-up.
MedLine Citation:
PMID:  18216575     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To report the efficacy of topical cyclosporine A (CsA) 0.05% drops (Restasis; Allergan, Irvine, CA) in the treatment of superior limbic keratoconjunctivitis (SLK). METHODS: Seven patients with SLK refractory to corticosteroid drops and topical silver nitrate application were treated with 0.05% topical CsA 4 times a day, preservative-free artificial tears, and a lubricant ointment. The patients were evaluated for symptomatic and clinical improvement after 2 weeks, 1 month, 3 months, 6 months, and in 6 patients, >12 months. RESULTS: After 2 weeks of topical CsA treatment, symptoms of foreign-body sensation, irritation, and photophobia and signs of conjunctival hyperemia, tarsal papillary reaction, and filamentous keratopathy improved remarkably in all patients. The patients had some burning of short duration after administration of topical CsA. However, none of them suffered from systemic or serious local side effects. After cessation of the topical CsA treatment, 6 patients were followed up for at least 6 months. In this period, the patients continued using lubricant agents. Three patients (50%) showed signs of recurrence after 3 months, and topical CsA was restarted. The clinical findings improved again within a 2-week period, and none of these patients needed further use of topical steroids. CONCLUSIONS: Topical CsA 0.05% can be effective in patients with SLK who do not respond to other treatment modalities. It can also be used in the long term to prevent recurrences during treatment and to avoid steroid dependency and the side effects of steroids.
Afsun Sahin; Banu Bozkurt; Murat Irkec
Related Documents :
18850565 - Effective treatment with topical cyclosporine of a child with steroid-dependent interst...
11233655 - Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory b...
22890655 - Endovascular management of posthemorrhagic cerebral vasospasm: indications, technical n...
18343615 - Methotrexate as single therapy in crohn's disease: is its long-term efficacy limited?
22433195 - Interventional catheterisation of stenotic or occluded systemic veins in children with ...
23977155 - Implicit trust between the uyghur and the han in xinjiang, china.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cornea     Volume:  27     ISSN:  0277-3740     ISO Abbreviation:  Cornea     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-24     Completed Date:  2008-03-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  193-5     Citation Subset:  IM    
Department of Ophthalmology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Cyclosporine / administration & dosage*
Follow-Up Studies
Immunosuppressive Agents / administration & dosage*
Keratoconjunctivitis / drug therapy*
Limbus Corneae / drug effects*
Middle Aged
Ophthalmic Solutions / administration & dosage
Treatment Outcome
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Ophthalmic Solutions; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Three VSX1 gene mutations, L159M, R166W, and H244R, are not associated with keratoconus.
Next Document:  Surgical approach for scleral ischemia and melt.